Structural Genomics Consortium, CHDI Launch Open-access Huntington's Disease Initiative | GenomeWeb

NEW YORK (GenomeWeb) – The Structural Genomics Consortium and the CHDI Foundation have struck an agreement to discover and characterize new drug targets for Huntington's disease and to make their findings available for use by academic researchers and pharmaceutical and biotechnology companies.

Neither the SGC nor CHDI will file for patents on any of their research findings, but will make all the reagents and knowledge they generate widely available without restrictions, the partners said yesterday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.